JNJJanssen Research & Development, LLCRunning, no new patients
A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations
Urothelial Cancer
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2
4 insiders sold shares within a month
Since Aug 17, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 3
- Patients
- 629 (final count)
- Started
- Mar 23, 2018
- Main results expected
- Apr 15, 2024
- Fully finished
- Dec 31, 2027
- Results posted
- May 14, 2025
What counts as success
The trial's main goal(s), called the “primary outcome.”
Overall Survival (OS)
Measured over: From randomization (3 days prior to Cycle 1 Day 1) until death due to any cause (maximum up to 51.7 months)
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2, since 2026-08-17, fades (half-life)
Raw record changes
- none yet
Trial ID NCT03390504 · record last updated 2026-11-03 · checked 2026-11-09 15:42 UTC